Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147


Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP.

Cell. 1999 Oct 29;99(3):323-34.


Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.

Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H.

Cancer Res. 2000 Dec 15;60(24):7033-8.


PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase.

Wu Y, Dowbenko D, Pisabarro MT, Dillard-Telm L, Koeppen H, Lasky LA.

J Biol Chem. 2001 Jun 15;276(24):21745-53. Epub 2001 Mar 2.


Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.

Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK.

Oncogene. 2002 Apr 4;21(15):2357-64.


The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.

Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP.

Biochem J. 2004 Apr 15;379(Pt 2):301-7.


The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.

Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7.


Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase.

Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, Lasky LA.

J Biol Chem. 2000 Jul 14;275(28):21477-85.


Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.

Downes CP, Walker S, McConnachie G, Lindsay Y, Batty IH, Leslie NR.

Biochem Soc Trans. 2004 Apr;32(Pt 2):338-42. Review.


Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.

Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A.

Science. 2004 Feb 20;303(5661):1179-81.


Membrane-binding and activation mechanism of PTEN.

Das S, Dixon JE, Cho W.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7491-6. Epub 2003 Jun 13.


Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.

Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamaru R, Ishioka C.

Cancer Res. 2000 Jun 15;60(12):3147-51.


PTEN: The down side of PI 3-kinase signalling.

Leslie NR, Downes CP.

Cell Signal. 2002 Apr;14(4):285-95. Review.


Phosphorylation of the PTEN tail regulates protein stability and function.

Vazquez F, Ramaswamy S, Nakamura N, Sellers WR.

Mol Cell Biol. 2000 Jul;20(14):5010-8.


Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.

Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP.

Biochem J. 2001 Jul 15;357(Pt 2):427-35.


Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.

Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J.

Exp Cell Res. 2000 May 1;256(2):571-7.


PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R.

Science. 1997 Mar 28;275(5308):1943-7.


A PTEN-like phosphatase with a novel substrate specificity.

Pagliarini DJ, Worby CA, Dixon JE.

J Biol Chem. 2004 Sep 10;279(37):38590-6. Epub 2004 Jul 9.

Items per page

Supplemental Content

Write to the Help Desk